S

SCI Pharmtech Inc
TWSE:4119

Watchlist Manager
SCI Pharmtech Inc
TWSE:4119
Watchlist
Price: 91 TWD 1.11% Market Closed
Market Cap: 10.9B TWD
Have any thoughts about
SCI Pharmtech Inc?
Write Note

SCI Pharmtech Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SCI Pharmtech Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
S
SCI Pharmtech Inc
TWSE:4119
Income from Continuing Operations
NT$484.2m
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
7%
Y
YungShin Global Holding Corp
TWSE:3705
Income from Continuing Operations
NT$1.1B
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
4%
Formosa Laboratories Inc
TWSE:4746
Income from Continuing Operations
NT$255.5m
CAGR 3-Years
-39%
CAGR 5-Years
15%
CAGR 10-Years
0%
ScinoPharm Taiwan Ltd
TWSE:1789
Income from Continuing Operations
NT$399.4m
CAGR 3-Years
26%
CAGR 5-Years
9%
CAGR 10-Years
-6%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Income from Continuing Operations
NT$4.3B
CAGR 3-Years
43%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Standard Chem & Pharm Co Ltd
TWSE:1720
Income from Continuing Operations
NT$1.2B
CAGR 3-Years
15%
CAGR 5-Years
21%
CAGR 10-Years
14%
No Stocks Found

SCI Pharmtech Inc
Glance View

Market Cap
10.9B TWD
Industry
Pharmaceuticals

SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others

Intrinsic Value
56.29 TWD
Overvaluation 38%
Intrinsic Value
Price
S

See Also

What is SCI Pharmtech Inc's Income from Continuing Operations?
Income from Continuing Operations
484.2m TWD

Based on the financial report for Sep 30, 2024, SCI Pharmtech Inc's Income from Continuing Operations amounts to 484.2m TWD.

What is SCI Pharmtech Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
7%

Over the last year, the Income from Continuing Operations growth was 28%.

Back to Top